论文部分内容阅读
目的对80例糖尿病肾病伴有高血压病患者,随机分为治疗组40例,应用依那普利治疗干预,并与使用硝苯地平地平的40例对照组进行随机对照临床观察,了解其对24 h尿微量白蛋白的影响。结果治疗组24 h尿微量白蛋白、血清超敏C反应蛋白(hsCRP)有非常显著下降;而对照组hsCRP无明显变化,24 h尿微量白蛋白反而有显著升高。结论长期应用依那普利治疗糖尿病肾病患者,可有效控制血压,减少24 h尿微量白蛋白,血清C反应蛋白(CRP)有非常显著下降,进而防止肾功能进行性损害。显示其明显优于钙拮抗剂(CCB)硝苯地平对照组。
Objective To investigate 80 diabetic nephropathy patients with hypertension who were randomly divided into treatment group (n = 40) and enalapril treatment intervention (nifedipril treatment intervention), and were compared with 40 control group using nifedipine 24 h urine microalbumin impact. Results 24 h urine microalbuminuria and serum hsCRP decreased significantly in the treatment group, but there was no significant change in the control group hsCRP, 24 h urine microalbumin but significantly increased. Conclusion Long-term use of enalapril in patients with diabetic nephropathy can effectively control blood pressure, reduce 24-hour urine microalbuminuria, serum C-reactive protein (CRP) have a very significant decline, thereby preventing progressive renal damage. Showed significantly better than calcium antagonist (CCB) nifedipine control group.